Brand against brand · semaglutide and orforglipron
Wegovy vs Foundayo
From the two FDA labels, read Published by PepVault
Wegovy is semaglutide, a GLP-1 receptor agonist, from Novo Nordisk; Foundayo is orforglipron, a GLP-1 receptor agonist, from Eli Lilly.
FDA approved Wegovy for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and (the injection) the liver disease MASH. Foundayo is approved for weight loss and keeping it off, in adults with obesity or with overweight and a weight-related condition.
Label against label
| Compared | Wegovy | Foundayo |
|---|---|---|
| Active ingredient | semaglutide | orforglipron |
| Class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Maker | Novo Nordisk | Eli Lilly |
| Approved for | Weight reduction; heart risk with obesity; MASH (injection) | Weight reduction |
| Forms | Single-dose pen; Single-dose syringe; FlexTouch pen; Tablet | Tablet |
| How often | once a week or once a day | once a day |
| Starting dose | 0.25 mg a week (injection); 1.5 mg a day (tablets) | 0.8 mg a day |
| Top dose on the label | 7.2 mg a week (injection); 25 mg a day (tablets) | 17.2 mg a day |
| Most reported side effect | Nausea, 44% on 2.4 mg (placebo 16%) | Nausea, 35% on 17.2 mg (placebo 10%) |
| Boxed warning | “RISK OF THYROID C-CELL TUMORS” | “RISK OF THYROID C-CELL TUMORS” |
| First approved | 2021 | 2026 |
Each label’s side-effect figure comes from its own trials, at its own doses and in its own patients; as the labels themselves say, rates from different trials can’t be compared directly.
The two dosing schedules
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Wegovy injection, once a week
Wegovy tablets, once a day
Foundayo, once a day

A missed dose, on each label
- Wegovy: For a missed injection, the label looks at the next scheduled dose: more than 2 days away, take the missed one as soon as possible; less than 2 days away, skip it. Missing 2 or more weeks in a row means starting the climb again from a lower dose.
- Foundayo: A missed Foundayo tablet is taken as soon as it’s remembered, without doubling the next one.
The trial evidence
Questions
What is the difference between Wegovy and Foundayo?
Wegovy is semaglutide, a GLP-1 receptor agonist; Foundayo is orforglipron, a GLP-1 receptor agonist. Their labels approve them for different uses and set different schedules.
What are Wegovy and Foundayo approved for?
Wegovy is approved for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and (the injection) the liver disease MASH. Foundayo is approved for weight loss and keeping it off, in adults with obesity or with overweight and a weight-related condition.
How often are Wegovy and Foundayo taken?
Wegovy is taken once a week or once a day, as an injection or a tablet; Foundayo once a day, as a tablet.
What are the dose ranges of Wegovy and Foundayo?
On their labels, Wegovy runs 0.25 mg to 7.2 mg once a week or 1.5 mg to 25 mg once a day, and Foundayo 0.8 mg to 17.2 mg once a day. A prescriber sets the actual dose.
What is the most common side effect of Wegovy and Foundayo?
On Wegovy’s label: nausea, 44% on 2.4 mg (placebo 16%). On Foundayo’s: nausea, 35% on 17.2 mg (placebo 10%).
Sources
- WEGOVY (semaglutide) injection, for subcutaneous use, and WEGOVY (semaglutide) tablets, for oral use, FDA label on DailyMed (version 19, published Jun 30, 2026; read Nov 18, 2026)
- FOUNDAYO (orforglipron) tablets, for oral use, FDA label on DailyMed (version 10, published Aug 13, 2026; read Nov 18, 2026)
- Drugs@FDA, NDA 215256 (Wegovy, the injection; application first approved 2021)
- Drugs@FDA, NDA 218316 (Wegovy, the tablets; application first approved 2025)
- Drugs@FDA, NDA 220934 (Foundayo, the tablets; application first approved 2026)
PepVault is not affiliated with Novo Nordisk. Wegovy is a trademark of its owner. PepVault is not affiliated with Eli Lilly. Foundayo is a trademark of its owner.